Background: Severe acute respiratory syndrome coronavirus 2 [SARS-COV2] is a serious infection nowadays. Infection is typically limited to the mucosal cells of the respiratory tract. At least 50% of infections are asymptomatic. Immunity is brief and reinfection occurs.
Aim of the work: Live attenuated and sub-unit vaccines development against SARS-COV2
Patients and Methods: This was a screening experimental study. In our study, we designed sub-unit vaccine [A] for coherent and conserved Spike[S] protein and other coherent and conserved structural and non-structural proteins of the virus using bio-informatics applications software. Also, we prepared live attenuated vaccine of SARS-COV2 [B].
Results: Both vaccines [A and B] resulted in 97 and 96% efficacy, respectively during preclinical trials [animal testing] while showed 86 and 84% protection power during human clinical trials phases 1-2. They showed superior biological activity and fewer side effects than other standard vaccines such as Pfizer and Astrazenca vaccines. Their efficacy lasted from 2-3 months for vaccine A and 6-8 months for vaccine B.
Conclusion: Both vaccines in our study were effective as prophylaxis against viral infection with SARS-COV2 and mutant forms of this virus. Booster doses are required to enhance immunity for both types of vaccines.